CRNX - Crinetics Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Crinetics Pharmaceuticals, Inc.

Building 2
10222 Barnes Canyon Road
San Diego, CA 92121
United States

Full Time Employees68

Key Executives

NameTitlePayExercisedYear Born
Dr. R. Scott StruthersFounder, Pres, CEO & Director783.8kN/A1962
Mr. Marc J. C. WilsonCFO & Sec.418.74kN/A1979
Dr. Alan S. KrasnerChief Medical Officer491.43kN/A1963
Dr. Yun-Fei ZhuFounder & VP of ChemistryN/AN/A1963
Dr. Stephen F. BetzCo-Founder & VP of BiologyN/AN/A1966
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and adrenocorticotrophic hormone antagonist for the treatment of cushing's diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

Corporate Governance

Crinetics Pharmaceuticals, Inc.’s ISS Governance QualityScore as of December 3, 2019 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.